GlobalData on MSN
Sino and AstraZeneca sign licence agreement for TQC3721
Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca.
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...
In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...
Sino Biopharma’s subsidiary, CTTQ further deepens the exclusive strategic collaboration with GSK: Hong Kong Friday, July 10, 2026, 16:00 Hrs [IST] Sino Biopharmaceutical Limited ...
Sino Biopharmaceutical enters exclusive license agreement with AstraZeneca for development, manufacturing and commercialization of PDE3/4 inhibitor, TQC3721: Hong Kong Thursday, J ...
In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results